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Streszczenie 
Zespoły paranowotworowe są to objawy lub zespoły objawów towarzyszące chorobie nowotworowej, które często ustępu-
ją po skutecznym wyleczeniu nowotworu. Przyczyny zespołów paranowotworowych nie zostały w pełni poznane. Mechani-
zmy związane są z nieprawidłowym wydzielania hormonów lub cytokin, a także z wytwarzaniem przeciwciał skierowanych 
przeciw nowotworowi. Najczęstsze zespoły paranowotworowe objawiają się pod postacią zespołów neurologicznych, 
zaburzeń hematologicznych, zmian skórnych. Artykuł przedstawia związek nowotworów złośliwych z autoimmunologicz-
nymi chorobami tkanki łącznej. 
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Introduction
Paraneoplastic syndromes are a group of rare disorders 
related to the presence of cancer, but independent of the 
tumour’s location or size. Due to the fact that cancers 
are more common in aged populations, paraneoplastic 
syndromes also typically occur in the elderly.
Symptoms of paraneoplastic syndromes may precede, 
accompany or coincide with onset of cancer, but they mostly 
appear during the first 2 years before cancer is diagnosed.
This article presents typical rheumatic entities which 
may be related to or directly caused by the expansive pro-
cess ongoing within the body.
The relation between cancer and autoimmune rheu-
matic diseases is sufficiently understood; it is assumed 
that progression of the process may occur due to activa-
tion of multiple potential mechanisms. Cancer may occur 
as a consequence of rheumatic diseases due to chronic 
inflammation in the tumour microenvironment [1, 2], dama-
ge caused by the rheumatic process or cytostatic therapy.
Conversely, a rheumatic disease may occur as a con-
sequence of cancer (pure paraneoplastic syndromes), 
due to a cancer-induced autoimmune response or as 
a consequence of the immunotherapy or chemotherapy 
utilized in cancer treatment. For example, administration 
of bleomycin, vinblastine, vincristine or cisplatin may lead 
to Raynaud syndrome, while using aromatase inhibitors 
may contribute towards development of arthritis and 
myositis.
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Approx. 15% of cancer patients develop paraneoplastic 
syndromes as a result of action of tumour-derived biologic 
mediators, such as hormones, peptides, antibodies, cytoto-
xic lymphocytes, autocrine and paracrine mediators [3, 4].
Patients with paraneoplastic syndromes may develop 
autoantibodies many years before clinical symptoms [5]. 
Similarly, autoantibodies in neoplastic sera may be de-
tected many years before cancer is diagnosed [6–8]. The 
presence of autoantibodies in sera of patients with solid 
or hematologic tumours has been documented by several 
studies [9–14]. All data concerning cancer-related autoa-
ntigens is collected in databases available at http://www.
cancerimmunity.org/peptide/.
The presence of antinuclear antibodies is detected in 
approx. 24% of patients with paraneoplastic syndromes, 
while in a group of people in whom antinuclear antibodies 
have been detected by coincidence, cancer incidence was 
estimated at approx. 2.9% [15, 16].
Various studies demonstrate the relation between an-
tibodies characteristic for rheumatic diseases and cancer 
incidence. In a report by Zuckerman et al., anticardiolipin 
antibodies were present in 22% of neoplastic sera, com-
pared to 3% for healthy population in control group [17]. 
Lossos et al. detected antiphospholipid antibodies in 68% 
of sera from patients with acute myeloid leukaemia [18]. 
Meanwhile, Crawford et al. described antibodies against 
human p53 in 9% of sera from breast cancer patients. 
These findings were confirmed by Caron de Fromentel et 
al., who found anti-p53 antibodies in 21% of sera from 
children with B-cell lymphoma [19].
Finally, autoantibodies against c-myc have been descri-
bed in sera from patients with breast and colorectal cancer, 
as well as with scleroderma, systemic lupus erythematosus 
and dermatomyositis [20–22].
These observations prove a significant autoimmune 
response activation, resulting in production of antibodies 
which also take part in pathogenesis of autoimmune and 
rheumatic diseases.
Polyarthritis
Paraneoplastic arthritis is a seronegative arthritis which 
may occur before cancer diagnosis. Typical symptoms inclu-
de muscle pains and morning stiffness. Joint pains involve 
hands, ankles and knees. Characteristic features include 
reduced prevalence of RF and anti-CCP antibodies, increa-
sed concentration of LDH and CRP and visibly accelerated 
ESR compared to regular arthritis. Other features helpful 
in differential diagnosis are asymmetric joint involvement, 
dominance of elderly patients, dominance of male sex and 
steroid resistance.
The period between diagnosis of paraneoplastic arthri-
tis and diagnosis of malignant neoplasm is shorter than 
a year. Although nearly all cancers may involve development 
of arthritis, most data concerns lymphomas, both NHL and 
HL, as well as breast cancer in women and lung cancer 
in men.
As mentioned in the introduction, anti-cancer therapies 
may lead to arthritis. The main culprits are cyclophospha-
mide, 5-fluorouracil, tamoxifen, methotrexate and cisplatin. 
Aromatase inhibitors are related to joint pains and loss of 
bone mineral density. Studies indicate that 47% of arthritis 
symptoms develop 2–3 months after administration of 
aromatase inhibitors has started.
Hypertrophic osteoarthropathy
It is characterized by clubbed fingers, synovitis of 
neighbouring joints, periosteal reaction visible on X-ray ima-
ges, tibia and femur pains and joint pains. This syndrome 
occurs in respiratory system cancers.
Palmar fasciitis and polyarthritis
This syndrome is characterized by bilateral contracture 
of distal phalanges, fasciitis, fibrosis and polyarthritis. It 
occurs in ovarian cancer, endometrial cancer, stomach 
cancer, pancreatic cancer, prostate cancer, cervical cancer 
and in Hodgkin disease.
Inflammatory myopathies
Polymyositis (PM) is an idiopathic inflammatory my-
opathy involving striated muscle tissue. The second syn-
drome from this group — Dermatomyositis (DM) — is an 
idiopathic inflammatory myopathy with skin manifestations. 
Both are characterized by acute or subacute onset, symme-
tric proximal muscle weakness, infiltration of mononuclear 
cells into muscle tissue and increased activity of muscle 
enzymes. Risk factors for DM/PM patients include: age 
> 45 years, male sex, skin necrosis, dysphagia, duration 
of disease < 4 months, ESR > 40 mm/h, high CRP concen-
tration and high phosphocreatine kinase activity, presence 
of anti-p155 antibodies. Studies indicate that the risk of 
a malignant neoplasm is significantly reduced in PM/DM 
patients with concomitant interstitial lung disease, arthral-
gia, Raynaud syndrome.
Several studies proved that cancer may occur before, 
at the same time as or after diagnosis of myositis. Cancer 
risk is much higher within the first 3 years of diagnosis 
[23]. Polymyositis is most common in tracheal cancer, lung 
cancer and non-Hodgkin lymphoma. On the other hand, 
dermatomyositis is related to stomach cancer, colorectal 
cancer, pancreatic cancer, prostate cancer, breast cancer 
and ovarian cancer, as well as tracheal/lung cancer and 
NHL.
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Vasculitis
The term cutaneous vasculitis encompasses a wide and 
heterogeneous range of syndromes, clinically characteri-
sed by inflammatory process involving vessels of various 
calibres and consequential skin damage, wherein usually 
a typical histopathological picture is established [24]. Va-
sculitis may be related to malignant neoplasms and may 
behave like a paraneoplastic syndrome. Palpable purpura 
is the most common skin manifestation. Patients with pa-
raneoplastic vasculitis are usually elderly and the syndrome 
more frequently involves significant areas of the skin; on the 
other hand, gastrointestinal tract and kidney involvement 
is observed less frequently compared to typical vasculitis 
cases. Furthermore, these patients more often suffer from 
anaemia, accelerated ESR and cytopenia. Paraneoplastic 
cutaneous vasculitis is related to the presence of a solid 
tumour. Lung cancer (non-small cell), prostate cancer, co-
lon cancer, kidney cancer, breast cancer, head and neck 
cancer (squamous cell) and endometrial cancer are the 
most common non-hematologic cancer types associated 
with cutaneous vasculitis [25].
Erythromelalgia
Erythromelalgia, that is painful erythema of the ex-
tremities, is a vasomotor disorder involving paroxysmal 
redness and warming of the distal parts of extremities, 
usually toes rather than fingers, accompanied by intense, 
burning pain. As a paraneoplastic syndrome, it is related to 
myeloproliferative disorders and thrombocythaemia in the 
course of systemic connective tissue diseases and chronic 
myeloid leukaemia.
RS3PE syndrome (remitting seronegative symmetrical 
synovitis with pitting oedema).
This syndrome is characterised by symmetrical synovitis 
of the hands and ankles with oedema, high concentration 
of acute-phase proteins, negative RF and no features 
of structural joint damage in radiographic examination. 
There is considerable oedema on the dorsal part of the 
palm, which makes grabbing difficult; it is caused mainly 
by extensor tenosynovitis.
Several cases of cancer involving RS3PE have been 
described thus far. The most commonly named types in-
clude Hodgkin’s lymphoma, leukaemias, myelodysplastic 
syndromes, T-cell lymphocytic leukaemia, prostate cancer, 
lung cancer, breast cancer, ovarian cancer, bladder cancer, 
endometrial cancer and malignant fibrous histiocytoma.
Prognosis for patients with RS3PE without concomitant 
cancer is excellent. Patients with RS3PE and cancer are 
characterised by weak response to glucocorticoid treatment 
and more dramatic systemic symptoms.
Lupus-like syndrome
This syndrome is characterised by skin lesions, arthritis, 
serositis, Raynaud’s phenomenon; other visceral compli-
cations are rare. Antinuclear antibodies may be present 
(usually in low titres), as can antiphospholipid antibodies; 
occasionally, leukopenia, thrombocytopenia or anaemia 
are also identified.
A metaanalysis of five prospective cohort studies 
published between 2002 and 2013 showed an increased 
risk of cancer of the haematopoietic system in patients 
with SLE [26]. This relation is particularly strong in case 
of non-Hodgkin lymphomas. Diffuse large B-cell lymphoma 
(DLBCL) is the most common type of NHL in SLE. Epide-
miologic studies were also able to identify increased risk 
of lung, liver and pancreatic cancer, but a decreased risk 
of breast and prostate cancer [27].
In addition, immunotherapy using interferon alpha 
and interferon gamma may also lead to development of 
a lupus-like syndrome.
Scleroderma-like syndrome
Scleroderma-like syndrome is one of the most common 
paraneoplastic syndromes. It is characterised by Raynaud’s 
phenomenon, thickening of the skin and pulmonary fibro-
sis. It typically develops in people over the age of 50; the 
onset of Raynaud’s phenomenon is sudden, skin lesions 
(on neck and torso, among others) progress quickly and 
sclerodactyly is present. Infrequently, high titres of anti-
nuclear antibodies and anti-topoisomerase I antibodies 
are also detected [28]. A study involving 23 patients with 
scleroderma and a concomitant cancer diagnosis from the 
cohort of the Johns Hopkins Scleroderma Centre showed 
that patients with autoantibodies against RNA polymerase 
III were more at risk of cancer progression, while no time 
dependency was found in patients with anti-centromere 
antibodies or anti-topoisomerase I antibodies. Patients 
were characterised by an enhanced expression of RNA 
polymerase III in cancerous tissues, suggesting a relation 
between tumour autoantigen expression and scleroderma-
-specific immune response [29].
Advanced age at the moment of scleroderma diagnosis 
was a strong predictor of shorter interval between cancer 
and scleroderma. For people in whom scleroderma deve-
loped at a young age, development of a tumour is a conse-
quence of immunosuppressive therapies, damage caused 
by the disease itself or environmental exposure rather than 
occurrence of pure paraneoplastic syndrome mechanisms. 
Cancer risk in this population was higher within the first 
12 months of cutaneous scleroderma diagnosis, gradually 
decreasing with the duration of the disease [30].
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Given the nearly universal occurrence of Raynaud’s 
phenomenon in patients with scleroderma, one should not 
forget adverse effects of certain cytostatic drugs, such as 
bleomycin, vinblastine, vincristine or cisplatin, which may 
lead to Raynaud syndrome [31]. Such clinical situations 
should be interpreted critically, as they are not examples 
of onset of a rheumatic disease in a patient undergoing 
chemotherapy, but constitute an instance of adverse effect 
of a drug. Occurrence of symptoms of scleroderma, or, more 
frequently, of a scleroderma-like syndrome, is typically 
linked with lung cancer; such relation is also encountered 
less frequently with stomach cancer, breast cancer, ovarian 
cancer, melanoma and multiple myeloma [32].
Sjögren syndrome
Sjögren syndrome is a systemic connective tissue 
disease, characterised by damage to the exocrine glands 
caused by inflammatory process. Immunologically, the basis 
of the disease is B-cell activation; this means that patients 
are particularly vulnerable to development of lymphomas.
Non-Hodgkin lymphomas are dominant cancer forms in 
Sjögren syndrome, and their incidence increases with time, 
encompassing approx. 10% of patients after the disease 
has continued for 30 years [33].
Lymphoma-related risk factors in Sjögren syndrome 
patients are well-known: persistent glandular itching, low 
C3 and C4 levels, cryoglobulinaemia, splenomegaly, leu-
kopenia, positive SSA/SSB.
Conclusions
Paraneoplastic syndromes constitute a conside-
rable problem in terms of diagnosis and therapy. In 
many cases they may represent the first symptom of 
a disease. In case of patients with a freshly diagnosed 
systemic connective tissue disease which resists stan-
dard treatment, with an unspecific course and atypical 
clinical picture, it is recommended to extend diagnosis 
to confirm or exclude a neoplastic background. Pro-
cedure in described syndromes does not differ from 
generally accepted principles applied in rheumatology, 
with simultaneous antineoplastic therapy. However, the 
possibility of withdrawal of rheumatic disease symptoms 
as the underlying neoplastic process is treated should 
be kept in mind.
Abstract
Paraneoplastic syndromes are symptoms or sets of symptoms accompanying cancer which often pass after said 
cancer is effectively treated. Causes of paraneoplastic syndromes are not fully understood. Mechanisms are related 
to abnormal hormone or cytokine secretion, as well as production of antibodies directed against the neoplasm. The 
most common paraneoplastic syndromes take the form of neurological syndromes, haematological disorders and skin 
lesions. The article presents the relation between malignant neoplasms and autoimmune connective tissue diseases.
Key words: paraneoplastic syndromes, malignant neoplasms, connective tissue diseases
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